Harrow Health Inc SEC Filings

Nasdaq Stock Market LLC has filed a Form 25 notification to remove the class of securities of Harrow, Inc. (HROW) from listing and/or registration on the Nasdaq exchange. The filing identifies the issuer and exchange and certifies Nasdaq believes it meets the requirements to submit this notice. The document does not include a signed signature block or detail which rule provision was checked for the removal.

Harrow, Inc. reported a leadership change at its wholly owned subsidiary ImprimisRx, LLC. On October 6, 2025, John Saharek ceased serving as President and Chief Executive Officer of ImprimisRx and certain affiliated entities, effective that date. He has moved into a non-officer leadership role at Harrow and will no longer be involved in ImprimisRx’s operations. The company did not enter into any new compensatory arrangements with him in connection with this transition.

Harrow also issued a press release on October 6, 2025, announcing these leadership changes at ImprimisRx, which is furnished as an exhibit and incorporated by reference.

Harrow, Inc. filed an amended current report to add full copies of key agreements for its planned acquisition of Melt Pharmaceuticals, Inc. as exhibits. The amendment attaches the Agreement and Plan of Merger dated September 24, 2025, among Harrow, its merger subsidiary, Melt, and D. Brad Osborne as stockholder representative, along with a related Milestone Payment Agreement between Harrow and Melt. The company states that no other changes are being made to the earlier report that first described the merger. Harrow also emphasizes that the representations, warranties and covenants in these agreements were made for the benefit of the parties as of specific dates and may use different materiality standards than investors, so they should not be read as full factual descriptions of the companies’ current condition.

Harrow, Inc. and certain subsidiaries entered into a new senior secured revolving credit agreement with Fifth Third Bank providing an initial facility of $40.0 million and an uncommitted incremental revolving line up to $20.0 million. The facility is secured and includes subsidiary guarantors, and it matures on September 26, 2030 or, if earlier, 91 days prior to the earliest maturity date of the company’s 8.625% senior notes due 2030. The credit line increases the company’s committed liquidity and provides flexibility through an additional uncommitted incremental option; the agreement names Fifth Third as administrative agent, letter of credit issuer, swing line lender, lead arranger and bookrunner.

Harrow, Inc. filed a current report to share materials from its Investor Day held on September 26, 2025. The company furnished an investor presentation as Exhibit 99.1, which was used at the event and in subsequent investor meetings. The information in the presentation and in this disclosure is furnished under Regulation FD and is expressly stated as not being deemed “filed” for purposes of Section 18 of the Exchange Act, nor automatically incorporated into other Securities Act or Exchange Act filings.

Harrow, Inc. has signed an Agreement and Plan of Merger to acquire all remaining equity of Melt Pharmaceuticals, a company in which Harrow already owns about 45% and holds a royalty on MELT-300. Because Harrow executives and directors also hold Melt equity and one serves on Melt’s board, the deal terms were negotiated and approved by an independent board committee, which obtained its own legal counsel and a fairness opinion.

At closing, Harrow will pay approximately $4.3 million in cash, with additional contingent payments tied to the MELT-300 program and its commercial performance. Upon FDA approval of MELT-300, Harrow would pay about $87.2 million in cash; upon CMS coding and reimbursement (including pass-through status and a J-Code or similar), it would issue roughly 1,112,000 Harrow common shares. One-time cash payments of up to about $261.0 million may be owed if annual net sales milestones between $100 million and $1.0 billion are achieved by December 31, 2035. Closing remains subject to customary conditions, including approval by Melt stockholders.

Harrow, Inc. (HROW) filed a Form 4 disclosing a stock option grant to Chief Accounting Officer Randall E. Pollard. On 09/01/2025 Mr. Pollard was granted an option to purchase 30,000 shares of common stock at an exercise price of $39 per share. The option expires on 09/01/2035 and is exercisable according to a vesting schedule: 25% at the one-year anniversary and the remainder vesting in 12 equal quarterly installments, becoming fully vested and exercisable on 09/01/2029. The filing was signed by an attorney-in-fact on 09/09/2025.

Randall E. Pollard, the Chief Accounting Officer of Harrow, Inc. (HROW), filed an initial Form 3 reporting that he does not beneficially own any securities of the company. The event requiring the statement is dated 09/01/2025 and the form was signed and filed via attorney in fact Andrew R. Boll on 09/09/2025. The filing serves as the required Section 16 disclosure for an officer but shows no stock ownership or derivative positions to report.

Harrow, Inc. disclosed that it has priced an offering of $250.0 million aggregate principal amount of its 8.625% senior unsecured notes due 2030 in a private transaction. The notes are being offered to qualified institutional buyers in the U.S. under Rule 144A and to certain non-U.S. investors in offshore transactions under Regulation S.

The company announced the pricing through a press release dated September 8, 2025, which is incorporated by reference as an exhibit. The disclosure emphasizes that this communication is not an offer or solicitation to buy or sell securities in any jurisdiction where such activity would be unlawful.